Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1 Receptor Agonists in Chronic Kidney Disease

What this Trial Is About

Researchers are evaluating the relationship between adiposopathy, a malfunction of fat tissue, and chronic kidney disease (CKD), a condition where kidney function progressively worsens. This study focuses on patients with CKD stages 1 to 4 who also have type 2 diabetes, cardiovascular diseases, or obesity. The study aims to understand how treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA), such as semaglutide and tirzepatide, affects adiposopathy and related kidney and heart risks. CKD progression is linked to increased cardiovascular risk, especially in severe stages requiring dialysis, and adiposopathy may worsen this risk through inflammation. Participants will be in one of several groups receiving different treatments: weekly subcutaneous injections of GLP-1RA (semaglutide or tirzepatide) with dose escalation, daily oral SGLT2 inhibitors, or other standard CKD care medications not involving GLP-1RA or SGLT2 inhibitors. The treatment phase lasts 16 months, during which changes in adipose tissue thickness around organs and kidney function will be monitored using ultrasound and blood tests. Throughout the 16 months, participants will undergo evaluations including ultrasound measurements of various fat tissue areas, blood tests for markers like leptin and adiponectin, and urine tests for kidney injury indicators. Researchers will track changes in fat tissue distribution and kidney function to assess treatment effects. Participants will provide informed consent and be monitored periodically to measure the study outcomes and safety.

Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD